Cargando…

Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma

BACKGROUND: There are currently no circulating biomarkers used for clinical monitoring of clear cell renal cell carcinoma (ccRCC). Such a biomarker could facilitate individualized treatment decisions and minimize exposure to ineffective therapies. Prior studies have suggested that circulating KIM-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Wenxin, Vemula, Sai V, Niman, Samuel M, Liu, Xiaowen, Takakura, Ayumi, Huang, Zimo, Choueiri, Toni K, Freedman, Matthew L, Catalano, Paul J, Bonventre, Joseph V, Gupta, Saurabh, McDermott, David F, Bhatt, Rupal S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Oral Abstract Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445574/ http://dx.doi.org/10.1093/oncolo/oyad216.004

Ejemplares similares

KIM-1/TIM-1 in proximal tubular cell immune response
por: Brooks, Craig R., et al.
Publicado: (2015)

Kim-1/Tim-1 and Immune cells: Shifting Sands
por: Ichimura, Takaharu, et al.
Publicado: (2012)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Kim /
por: Kipling, Rudyard, 1865-1936
Publicado: (1999)

Kim /
por: Kipling, Rudyard, 1865-1936
Publicado: (1986)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Urinary KIM-1 is not correlated with gestational age among 5-year-old children born prematurely
por: Restrepo, Jaime M., et al.
Publicado: (2023)

Fever, fear and hunger: the response of the Irish population to infectious disease during the Great Irish Famine, 1845-48
por: McDermott, R
Publicado: (2012)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Kim il sung : biography (II)
por: Bong, Baik
Publicado: (1970)

Kim il sung : biography (II)
por: Bong, Baik
Publicado: (1970)

In Memory of Chong-Sun Kim
por: Oh, Seung-Ha
Publicado: (2020)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

Kim Zong Il : dirigente del pueblo
por: Che In Su
Publicado: (1983)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Chrysospleniumramosissimum Y.I.Kim & Y.D.Kim (Saxifragaceae), a new species from Korea
por: Kim, Yong-In, et al.
Publicado: (2018)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Cherishing the memory of Professor Sang-In Kim
por: Kwon, Seog-Woon
Publicado: (2011)

In Memory of Soon Yong Kim, MD
por: Lim, Jae Hoon
Publicado: (2014)

In Memory of Professor Chu-Wan Kim
por: Lee, Jae Young
Publicado: (2015)

Isaac McKim McCurley
Publicado: (1869)

Speaker 4: Kim Do,Switzerland
por: Dwir, Daniella, et al.
Publicado: (2016)

First person – Kim Anh Nguyen
Publicado: (2019)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

Tae Hoon Kim: Knows his boundaries
por: Williams, Ruth
Publicado: (2008)

Heroes of peer review: Hyongbum (Henry) Kim
por: Kim, Hyongbum
Publicado: (2016)

Speaker: Sung Wan Kim, Republic of Korea
Publicado: (2016)

Response to the comment of Perone by the corresponding author Kim
por: Kim, Yongmoon, et al.
Publicado: (2023)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Multifunctional properties of Lactobacillus plantarum strains WiKim83 and WiKim87 as a starter culture for fermented food
por: Jung, Ji‐Hye, et al.
Publicado: (2019)

The complete chloroplast genome of a Korean endemic plant Chrysosplenium aureobracteatum Y.I. Kim & Y.D. Kim (Saxifragaceae)
por: Kim, Yong-In, et al.
Publicado: (2018)

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
por: Atkins, Michael B., et al.
Publicado: (2022)

S217: POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
por: Guolo, Fabio, et al.
Publicado: (2023)

O009 Are there Differences in SpO2 Recordings from Two Oximeters on the same hand during an Overnight Sleep Study Significant?
por: McDermott, E, et al.
Publicado: (2023)

La Corea contemporánea y Kim Zong Il
por: Shuhachi, Inoue
Publicado: (1984)

KIM-1 and NGAL: new markers of obstructive nephropathy
por: Wasilewska, Anna, et al.
Publicado: (2011)

Urine NGAL and KIM-1 in children and adolescents with hyperuricemia
por: Tomczak, Justyna, et al.
Publicado: (2013)

To Memorize Late Emeritus Professor Young Pio Kim
por: Lee, Seung-Chul
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vvb86lo2c3bjiaei9lavhb6e7r